227 related articles for article (PubMed ID: 2839658)
1. Age-related differences in the sensitivity of serum luteinizing hormone to prototypic mu, kappa and delta opiate agonists and antagonists.
Cicero TJ; Meyer ER; Miller BT; Bell RD
J Pharmacol Exp Ther; 1988 Jul; 246(1):14-20. PubMed ID: 2839658
[TBL] [Abstract][Full Text] [Related]
2. Naloxone does not reverse the inhibitory effect of morphine on luteinizing hormone secretion in prepubescent male rats.
Cicero TJ; Nock B; O'Connor L
J Pharmacol Exp Ther; 1993 Jan; 264(1):47-53. PubMed ID: 8380870
[TBL] [Abstract][Full Text] [Related]
3. Ontogeny of the opioid-mediated control of reproductive endocrinology in the male and female rat.
Cicero TJ; Schmoeker PF; Meyer ER; Miller BT; Bell RD; Cytron SM; Brown CC
J Pharmacol Exp Ther; 1986 Mar; 236(3):627-33. PubMed ID: 3512817
[TBL] [Abstract][Full Text] [Related]
4. Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat.
Iyengar S; Kim HS; Wood PL
J Pharmacol Exp Ther; 1986 Aug; 238(2):429-36. PubMed ID: 3016237
[TBL] [Abstract][Full Text] [Related]
5. Identification of multiple opiate receptors through neuroendocrine responses. II. Antagonism of mu, kappa and sigma agonists by naloxone and WIN 44,441-3.
Pechnick R; George R; Poland RE
J Pharmacol Exp Ther; 1985 Jan; 232(1):170-7. PubMed ID: 2981314
[TBL] [Abstract][Full Text] [Related]
6. Age-related differences in the sensitivity to opiate-induced perturbations in reproductive endocrinology in the developing and adult male rat.
Cicero TJ; O'Connor L; Nock B; Adams ML; Miller BT; Bell RD; Meyer ER
J Pharmacol Exp Ther; 1989 Jan; 248(1):256-61. PubMed ID: 2643703
[TBL] [Abstract][Full Text] [Related]
7. Opiate-induced enhancement of the effects of naloxone on serum luteinizing hormone levels in the male rat: specificity for Mu agonists.
Cicero TJ; Owens DP; Schmoeker PF; Meyer ER
J Pharmacol Exp Ther; 1983 Sep; 226(3):770-5. PubMed ID: 6310081
[TBL] [Abstract][Full Text] [Related]
8. Opiate withdrawal-induced hyposensitivity to naloxone's effects on serum luteinizing hormone in the male rat.
Cicero TJ; Aleem A; Meyer ER; Schmoeker PF; Miller BT
J Pharmacol Exp Ther; 1986 Sep; 238(3):1063-70. PubMed ID: 3528453
[TBL] [Abstract][Full Text] [Related]
9. In vivo studies on spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a differential association of mu, delta and kappa receptors with visceral chemical and cutaneous thermal stimuli in the rat.
Schmauss C; Yaksh TL
J Pharmacol Exp Ther; 1984 Jan; 228(1):1-12. PubMed ID: 6319664
[TBL] [Abstract][Full Text] [Related]
10. Place-conditioning properties of mu, kappa, and sigma opioid agonists.
Iwamoto ET
Alcohol Drug Res; 1985-1986; 6(5):327-39. PubMed ID: 3011025
[TBL] [Abstract][Full Text] [Related]
11. Luteinizing hormone releasing hormone mediates naloxone's effects on serum luteinizing hormone levels in normal and morphine-sensitized male rats.
Cicero TJ; Schmoeker PF; Meyer ER; Miller BT
Life Sci; 1985 Aug; 37(5):467-74. PubMed ID: 3894852
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro studies on the opioidergic control of the secretion of gonadotrophin-releasing hormone and luteinizing hormone in sexually immature and adult male rats.
Leposavic G; Cover PO; Buckingham JC
Neuroendocrinology; 1991 Jun; 53(6):579-88. PubMed ID: 1652110
[TBL] [Abstract][Full Text] [Related]
13. Effects of the novel opiate antagonist, SDZ 210-096, on luteinizing hormone secretion in the rat.
Siegel RA; Révész L
J Pharmacol Exp Ther; 1989 Apr; 249(1):264-70. PubMed ID: 2540315
[TBL] [Abstract][Full Text] [Related]
14. Development of acute tolerance to the effects of naloxone on the hypothalamic-pituitary-luteinizing hormone axis in the male rat.
Owens DP; Cicero TJ
J Pharmacol Exp Ther; 1981 Jan; 216(1):135-41. PubMed ID: 7005427
[TBL] [Abstract][Full Text] [Related]
15. Further study of kappa opioids on increased urination.
Leander JD
J Pharmacol Exp Ther; 1983 Oct; 227(1):35-41. PubMed ID: 6137557
[TBL] [Abstract][Full Text] [Related]
16. Continuous intrathecal opioid analgesia: tolerance and cross-tolerance of mu and delta spinal opioid receptors.
Russell RD; Leslie JB; Su YF; Watkins WD; Chang KJ
J Pharmacol Exp Ther; 1987 Jan; 240(1):150-8. PubMed ID: 3027302
[TBL] [Abstract][Full Text] [Related]
17. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A
J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of opiate-induced depressions in serum luteinizing hormone levels by the prior administration of naloxone in the male rat.
Cicero TJ; Owens DP; Schmoeker PF; Meyer ER
Life Sci; 1984 Sep; 35(12):1321-8. PubMed ID: 6090834
[TBL] [Abstract][Full Text] [Related]
19. Naloxone blocks the effects of delta 9-tetrahydrocannabinol on serum luteinizing hormone and prolactin in rats.
Kumar MS; Simpkins JW
Subst Alcohol Actions Misuse; 1983; 4(5):347-53. PubMed ID: 6322367
[TBL] [Abstract][Full Text] [Related]
20. Exogenous and endogenous opioid-induced enhancements of naloxone's effects on serum luteinizing hormone levels in the male rat.
Cicero TJ; Owens DP; Newman KS; Schmoeker PF; Meyer ER
Eur J Pharmacol; 1984 Oct; 105(3-4):273-84. PubMed ID: 6096156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
